These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1565 related articles for article (PubMed ID: 28435223)

  • 1. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
    Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
    Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
    Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
    Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
    Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
    Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells.
    Yu Y; Yu X; Ma J; Tong Y; Yao J
    Int J Oncol; 2016 Jul; 49(1):285-93. PubMed ID: 27176231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
    Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
    Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
    Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ
    Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.